Skip to content

Simultaneous and staged percutaneous nephrolithotomy and ureterorenoscopy for renal calculi combined with ureteral calculi

Percutaneous nephrolithotomy and ureterorenoscopy for renal calculi combined with ureteral calculi

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-13004146
Enrollment
Unknown
Registered
2013-10-03
Start date
2013-12-02
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary calculi

Interventions

the control group:staged percutaneous nephrolithotomy and ureteroren
the observation group:Simultaneous conduct percutaneous nephrolithotomy and ureteroren

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. To be aged 18 years or older; 2. renal and ureter stone need treat by PCNL and URL; 3. blood RBC = 1.5*10*9 platelet=100*10*9, hemoglobin =90g/L; 4. blood biochemical indexes: liver function: bilirubin = 1.5 times the upper limit of normal, AST = 2.5 times the upper limit of normal; serum creatinine =1.5 times the upper limit of normal serum calcium concentration: =12mg/dL; 5. coagulation function: PT = 1.5 times the upper limit of normal; 6. the following diseases did not appear within 6 months: myocardial infarction, severe or unstable angina, congestive heart failure, stroke or transient ischemic attack; 7. all the patients signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. renal decompensation need hemodialysis or peritoneal dialysis; 2. arrhythmia requiring antiarrhythmic therapy, symptomatic coronary artery disease or myocardial ischemia (myocardial infarction occurred in recent 6 months) or congestive heart failure than NYHA grade II; received 2 or more antihypertensive therapy has failed to control high blood pressure (systolic or diastolic blood pressure of >160mmHg >100 mmHg); 3. severe active clinicalinfection; 4. with coagulation disorders or bleeding physique; 5. patients cannot tolerate operation or anesthesia.

Design outcomes

Primary

MeasureTime frame
stone free rate;The complication rate;

Secondary

MeasureTime frame
average operating time;average hospital stay;average hospitalization expenses;average stent stay;

Countries

China

Contacts

Public ContactWang Jia

West China Hospital, Sichuan University

cdhx510@126.com+86 18980760199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 17, 2026